Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88(L265P) plasmablasts in vivo

The MYD88(L265P) mutation is found in 2% to 10% of chronic lymphocytic leukemia, 29% of activated B-cell type diffuse large B-cell lymphoma and 90% of Waldenström macroglobulinemia, making it conceptually attractive to treat these malignancies with inhibitors of endosomal Toll-like receptors (TLR9,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Wang, James Q., Beutler, Bruce, Goodnow, Christopher C., Horikawa, Keisuke
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2016
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5034740/
https://ncbi.nlm.nih.gov/pubmed/27458005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-03-708065
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars